arrow
Back
M

Martin Reck

german center for lung research

88H-index
627Paper Count
5.3WCitation Count
Published Papers 175
Publication Date
Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study
err2026-08-21
err0
PREAI
errH. Wakelee; J.D. Spicer; S. Gao; M. Liberman; M. Tsuboi; T. Kato; K.-N. Chen; C. Dooms; M. Majem; G.L. Martinengo; O. Bylicki; D. Rodríguez-Abreu; B. Halmos; D.R. Jones; J.E. Chaft; M. Reck; E. Jensen; S.M. Keller; A. Samkari; M.C. Garassino
errShare
errSave
Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer
err2026-06-30
err0
PREAI
errYago Garitaonaindia; Heather A. Wakelee; Martin Reck; Patrick M. Forde; Tina Cascone; Jonathan D. Spicer; Mariano Provencio
errShare
errSave
Left behind but not left alone: Excluded cell populations in the non-small cell lung cancer stroma predict superior long-term overall survival
err2026-06-09
err0
errOAAI
errSebastian Marwitz; Hans Brunnström; Miklos Gulyas; Johan Botling; Martin Reck; Christian Kugler; Hedvig Elfving; Patrick Micke; Carina Strell; Torsten Goldmann
errShare
errSave
Reduced Claudin-3 Expression Is Linked to Unfavorable Tumor Features and Poor Prognosis in Non-Small Cell Lung Cancer
err2026-01-06
err0
errOAAI
errNina Schraps; Martin Reck; Birgit Hantzsch-Kuhn; Till Olchers; David Benjamin Ellebrecht; Katharina Möller; Christoph Fraune; Maximilian Lennartz; Florian Lutz; Martina Kluth; Georgia Makrypidi-Fraune; Ronald Simon; Guido Sauter; Stefan Steurer; Sönke Von Weihe
errShare
errSave
Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score ≥50%: phase III study design
err2025-12-13
err0
errOAAI
errMartin Reck; Shun Lu; Kenneth J. O’Byrne; Carlos Barrios; Dmitri Pavlov; Fabian Tay; Marcelo V. Negrao
errShare
errSave
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations
err2025-12-03
err0
errOAAI
errTianshi Lu; Habib Hamidi; Mark A. Socinski; Martin Reck; Federico Cappuzzo; Fabrice Barlesi; Robert M. Jotte; Sören Müller; Aditi Qamra; Assaf Amitai; Xiangnan Guan; Eloisa Fuentes; Hartmut Koeppen; Jennifer M. Giltnane; David S. Shames; Marcus Ballinger; Meng Xiao He; Yulei Wang; Minu K. Srivastava; Barzin Y. Nabet
errShare
errSave
High GLUT1 protein expression is associated with unfavorable tumor features and poor prognosis in non-small cell lung cancer
err2025-11-30
err0
PREAI
errHantzsch-Kuhn, Birgit; Schraps, Nina; Reck, Martin; Olchers, Till; Ellebrecht, David Benjamin; Moeller, Katharina; Fraune, Christoph; Lennartz, Maximilian; Lutz, Florian; Kluth, Martina; Makrypidi-Fraune, Georgia; Simon, Ronald; Sauter, Guido; Steurer, Stefan
errShare
errSave
Effectiveness of NELSON versus PLCOm2012 lung cancer screening eligibility criteria in Germany (HANSE): a prospective cohort study
err2025-11-10
err0
errOAAI
errJens Vogel-Claussen; Benjamin-Alexander Bollmann; Katharina May; Susanne Stiebeler; Sabine Dettmer; Anton Faron; Alexander Kuhlmann; Gerald Schmid-Bindert; Rudolf Kaaks; Jörg Barkhausen; Sabine Bohnet; Martin Reck
errShare
errSave
Clinical Characteristics and Surgical Outcomes of Patients Receiving Perioperative Pembrolizumab in KEYNOTE-671
err2025-11-05
err0
PREAI
errMoishe Liberman; David R. Jones; Heather Wakelee; Shugeng Gao; Balazs Halmos; Ernest Nadal; Anna Łowczak; Martin Reck; Silvia Novello; Danielli Matias; Alexander Luft; Rina Hui; Se-Hoon Lee; Masahiro Tsuboi; Terufumi Kato; Yuming Zhu; Benny Weksler; Erin Jensen; Ayman Samkari; Steven M. Keller; Jonathan D. Spicer
errShare
errSave
White paper on identification, information, and eligibility assessment of potential participants in lung cancer screening in Germany (oct, 10.1055/a-2697-6434, 2025)
err2025-11-01
err0
errOAAI
errBlum, Torsten Gerriet; Vogel-Claussen, Jens; Hoffmann, Hans; Reck, Martin; Harth, Volker; Faron, Anton; Danschel, Ingrid; Andreas, Stefan; Rupp, Alexander; Kaaks, Rudolf; Schmid-Bindert, Gerald
errShare
errSave
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS <50% and ≥50% Cohorts of the EVOKE-02 Study
err2025-10-30
err0
PREAI
errMartin Reck; Jyoti D. Patel; Jhanelle E. Gray; Noemí Reguart; Manuel Cobo; José Fuentes Pradera; Enriqueta Felip; Federico Cappuzzo; Edward B. Garon; Joel W. Neal; Sabeen Mekan; Farnoush Safavi; Nelumka Fernando; Marianna Zavodovskaya; Juliane M. Jürgensmeier; Michael Chisamore; Byoung Chul Cho
errShare
errSave
Distinct genomic profile of pediatric lung carcinoma: High frequency of ALK fusions and TP53 mutations compared to adults
err2025-10-20
err0
errOAAI
errMichael Abele; Anton Karelin; Michaela Pogoda; Ulrike Faust; Sorin Armeanu-Ebinger; Jakob Admard; Alexandra Liebmann; Irina Bonzheim; Nicolas Waespe; Margo Hoover-Regan; Andreas Block; Martin Reck; Ewa Bien; Malgorzata Krawczyk; Dominik T. Schneider; Stephan Ossowski; Ines B. Brecht; Christopher Schroeder
errShare
errSave
Unresectable stage III non-small-cell lung cancer: state of the art and challenges
err2025-10-09
err0
PREAI
errJordi Remon; Antonin Levy; Romane Gille; Isabelle Martel-Lafay; Martina Bortolot; Lizza E. L. Hendriks; Corinne Faivre-Finn; Natasha Leighl; Martin Reck; Maurice Pérol
errShare
errSave
White paper on identification, information, and eligibility assessment of potential participants in lung cancer screening in Germany
err2025-10-01
err0
errOAAI
errBlum, Torsten Gerriet; Vogel-Claussen, Jens; Hoffmann, Hans; Reck, Martin; Harth, Volker; Faron, Anton; Danschel, Ingrid; Andreas, Stefan; Rupp, Alexander; Kaaks, Rudolf; Schmid-Bindert, Gerald
errShare
errSave
Interpreting immunogenicity in oncology clinical trials
err2025-08-25
err0
errOAAI
errPeter R. Galle; Martin Reck; David J. Pinato; Rosario Garcia-Campelo; Richard S. Finn; Sophie Cousin; Jim Zanghi; Coen A. Bernaards; Steven J. Swanson; Stefanie Morris; Yuan Song; Solange Peters
errShare
errSave
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
err2025-08-14
err0
PREAI
errMartin Reck; Nikolaj Frost; Solange Peters; Bernard A. Fox; Roberto Ferrara; Rajkumar Savai; Fabrice Barlesi
errShare
errSave
Digital Versus Manual PD-L1 Scoring in Advanced Non-Small Cell Lung Cancer From the IMpower110 and IMpower150 Trials
err2025-08-05
err0
PREAI
errRoy S. Herbst; Hen Prizant; Daniel Ruderman; Jake Conway; John Shamshoian; Hartmut Koeppen; Wei Zou; Filippo de Marinis; Giuseppe Giaccone; Jacek Jassem; David R. Spigel; Mark A. Socinski; Martin Reck; Luciana Molinero; Marcus Ballinger; David Shames; Michael Griffin; Limin Yu; Nishant Agrawal; Andrew Beck; Ilan Wapinski; Stephanie Hennek; Jennifer Giltnane; Minu K. Srivastava
errShare
errSave
First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study
err2025-08-05
err0
errOAAI
errRajiv Shah; Eva L. Buchmeier; Hans-Georg Kopp; Daniel C. Christoph; Frank Griesinger; Martin Reck; Petra Hoffknecht; Jonas Kuon; Nikolaj Frost; Christian Grohé; Martin Faehling; Jingting Luan; Julia Roeper; Paolo Chesi; Miriam Blasi; Martin Kimmich; Till Olchers; Helge Bischoff; Laura V. Klotz; Inn Chung; Petros Christopoulos; Michael Thomas
errShare
errSave
Adjuvant chemotherapy for stage IA–IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial
err2025-06-24
err0
errOAAI
errDavid R Spigel; Virginie Westeel; Ian C Anderson; Laurent Greillier; Florian Guisier; Olivier Bylicki; Firas B Badin; Gaelle Rousseau-Bussac; Clotilde Deldycke; Frank Griesinger; Adam Bograd; Wangjian Zhong; Jacques Le Treut; Sylvie Van Hulst; David R Gandara; Martin Reck; Petra Hoffknecht; Matthew A Gubens; John Crowley; Heiko von der Leyen; Gavitt A Woodard; David M Jablons; Johannes R Kratz; Michael J Mann
errShare
errSave